GHRH Analog (GRF 1-29) · Protocol Guide
Sermorelin: The Honest Guide Nobody Else Will Write
No marketing hype. No protocol mythology. What the clinical evidence actually says about GRF 1-29, including the timelines, the failure rates, and the questions the community is still arguing about in 2026.
Regulatory Status
Category 1: Compoundable
Pharmacy
Optimal Balance Pharmacy (503A licensed)
Medical Service
RxPepsDirect, physician-supervised
Access
33 U.S. States
Our promise: This guide leads with what sermorelin cannot do. We include non-responder rates, reversibility data, and side effect frequencies that clinics routinely skip. If something is not backed by clinical evidence, we say so.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.Section 01
What Sermorelin Actually Is
Sermorelin (GRF 1-29 NH2) is a synthetic analog of growth-hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of endogenous GHRH. It binds to GHRH receptors in the anterior pituitary gland and stimulates the natural, pulsatile release of your own growth hormone. It works with your hypothalamic-pituitary axis, not around it.
Sermorelin has a documented human history unlike most peptides in circulation. Marketed as Geref by Serono Laboratories, sermorelin received FDA approval in 1997 for one specific indication: diagnosing growth hormone deficiency in children and, later, treating idiopathic growth failure in children with confirmed GH deficiency. Geref was voluntarily discontinued in 2008 for commercial reasons, not safety concerns.
That distinction matters. In 2013 the FDA formally confirmed that Geref was not withdrawn from the market for safety or effectiveness reasons. That determination is the legal cornerstone that keeps sermorelin available as a compounded prescription drug today, when dozens of other peptides have been removed from the compounding supply chain.
29
Amino acids: the active N-terminal fragment of endogenous GHRH
10 to 20
Minute half-life. Requires daily dosing unlike CJC-1295
1997
FDA approval year for Geref, the only GHRH analog with this history
Section 02
Who It Is Actually For
Sermorelin works best for patients who understand they are optimizing a slow, physiological system. Candidates who expect dramatic transformation on a 30-day timeline are the most likely to discontinue before the compound has any meaningful opportunity to work.
| Profile | Primary Goal | Timeline Tolerance | Fit |
|---|---|---|---|
Longevity Architect Male, 45 to 65, often on TRT | GH axis optimization, IGF-1 elevation, long-term anti-aging | 6 to 12 months | Excellent |
Post-Ban Refugee Former CJC-1295 / Ipa user, 28 to 50 | Comparable body composition through legal channel | Expects faster, needs recalibration | Moderate with Education |
Perimenopausal Woman Female, 40 to 58 | Sleep restoration, energy, body composition, skin quality | Medium. Responds early to sleep improvement | Strong |
Wellness Biohacker 25 to 40, podcast-influenced | Rapid visible results, performance enhancement | Low. Expects week-4 results | Poor Without Reset |
TRT-Plus Patient Male, 40 to 70, existing TRT | Second-tier optimization on established hormonal foundation | 6 or more months, well-calibrated | Excellent |
Profile
Male, 45 to 65, often on TRT
Primary Goal
Timeline Tolerance
Fit
Profile
Former CJC-1295 / Ipa user, 28 to 50
Primary Goal
Timeline Tolerance
Fit
Profile
Female, 40 to 58
Primary Goal
Timeline Tolerance
Fit
Profile
25 to 40, podcast-influenced
Primary Goal
Timeline Tolerance
Fit
Profile
Male, 40 to 70, existing TRT
Primary Goal
Timeline Tolerance
Fit
Section 03
How It Works
Sermorelin binds to specific GHRH receptors on somatotroph cells in the anterior pituitary gland and triggers cyclic AMP-mediated signaling that stimulates GH synthesis and pulsatile secretion. The resulting GH release then acts on the liver and peripheral tissues to produce IGF-1, which drives the downstream anabolic and lipolytic effects patients seek.
The critical mechanistic distinction from exogenous HGH: sermorelin preserves the body's feedback architecture. When GH rises after a sermorelin injection, somatostatin still applies. IGF-1 still feeds back to inhibit further GH release. The hypothalamic-pituitary axis remains intact. That is why sermorelin's side effect profile is substantially better than synthetic HGH, and why IGF-1 levels typically stay within normal physiological ranges.
Why Sermorelin Requires More From You Than CJC-1295
The same mechanism that makes sermorelin safer also makes it demand more patient compliance. CJC-1295 with DAC has a half-life of 6 to 8 days, which allowed once-weekly injections. Sermorelin half-life is 10 to 20 minutes. Daily injections at a consistent time are mechanistically required to maintain the sustained pituitary stimulation necessary for meaningful IGF-1 elevation.
Section 04
Realistic Expectations, Honestly
This section exists because no clinic wants to publish it. The community most consistent grievance is calibration failure: expecting four-week results from a compound that requires six to twelve months. The dropout happens in months two and three, exactly when sermorelin is still building toward therapeutic effect.
"There's nothing you can use and look in the mirror two weeks later and ask if it's working. Sermorelin, and or ghrp2/6, et al., are long term commitments. 6-12 months minimum."
The Timeline That Matches Clinical and Community Data
Early Adaptation
Some users report altered dream intensity and mild vivid dreams. This is an early signal that sermorelin is active. No measurable fat or muscle changes expected.
Sleep Quality Signal
The earliest reproducible benefit: deeper sleep, easier morning wake, reduced nighttime fragmentation. The most reliable early indicator that the protocol is working.
IGF-1 Response Window
The earliest point at which lab-confirmed response should be detectable. If IGF-1 has not moved by week 6 to 8, your provider needs to evaluate dosing, adherence, and potential confounders.
Subjective Improvement Phase
Energy levels, recovery speed, and general wellbeing improvements appear for responders. This is the phase where uninformed patients most frequently quit, the most common and most preventable mistake.
Body Composition Assessment
The first meaningful window to assess lean mass and fat changes. Clinical literature suggests measurable shifts require consistent 3 to 6 month exposure combined with adequate dietary protein and resistance training.
Full Protocol Evaluation
The community and clinical literature agree: meaningful evaluation of sermorelin efficacy requires 6 to 12 months of consistent use with daily injection, bedtime timing, fasted administration, sleep optimization, and dietary compliance.
"3 years ago I used it for 6 months and really wish I had not wasted the money. It is expensive and you have to use it for 6 months to a year to even begin to maybe, if the lighting is just right, see or feel any difference whatsoever."
We include this quote because non-response is real, documented, and deserves honest acknowledgment. What separates a good clinical program from a telehealth mill is what happens when a patient does not respond: whether the provider investigates systematically or simply renews the prescription.
Section 05
Dosing Protocol
There is no FDA-approved dosing protocol for adult off-label sermorelin use. The protocols below represent the most evidence-adjacent options available, not evidence-based certainties. RxPepsDirect prescribing physicians select your starting dose based on baseline IGF-1, age, and clinical presentation.
| Protocol Context | Dose | Timing | Evidence Basis |
|---|---|---|---|
| RxPepsDirect Standard Protocol | 200 to 300 mcg per night | Bedtime, 2 or more hours fasted | Evidence-Adjacent |
| Community Standard | 200 to 300 mcg per night | Bedtime, fasted | Community Consensus |
| Older Male or Blunted Response | 400 to 500 mcg per night | Bedtime, fasted, physician-supervised only | Clinically Informed |
| Split Dose (dream disruption) | 100 to 150 mcg AM + 100 to 150 mcg bedtime | Fasted both doses | Community-Derived |
| Sublingual Troche / Tablet | Variable, clinic-dependent | Bedtime | Compromised Bioavailability |
Protocol Context
Dose
Timing
Evidence Basis
Protocol Context
Dose
Timing
Evidence Basis
Protocol Context
Dose
Timing
Evidence Basis
Protocol Context
Dose
Timing
Evidence Basis
Protocol Context
Dose
Timing
Evidence Basis
Standard Starting Dose
Draw to the 7-unit mark on a U-100 insulin syringe
7 units = 0.07 mL = 200 mcg
Daily injection, 30 minutes before bed, on an empty stomach. Subcutaneous into abdominal fat.
Escalated Dose
Draw to the 10-unit mark on a U-100 insulin syringe
10 units = 0.10 mL = 300 mcg
Used when IGF-1 response is suboptimal at standard dose. Adjusted only after week-6 IGF-1 review.
Section 06
Cycling: What the Evidence Says
The rationale for cycling sermorelin is theoretical rather than evidence-based: continuous GHRH receptor stimulation may produce receptor desensitization over time. Periodic rest is intended to restore receptor sensitivity. This model is biologically plausible but has not been tested in controlled adult trials.
| Protocol | On Period | Off Period | Community Rationale |
|---|---|---|---|
Conservative Cycle New users, first course | 8 to 12 weeks | 4 weeks | Establishes response baseline, limits commitment before efficacy confirmed |
Standard Cycle Confirmed responders | 12 to 16 weeks | 6 to 8 weeks | Most common protocol in community and telehealth practice |
Extended Cycle Longevity-focused | 16 to 20 weeks | 8 to 12 weeks | Maximizes cumulative GH exposure. Requires IGF-1 monitoring |
Continuous Use With regular IGF-1 monitoring | Ongoing | As indicated by labs | Preferred when IGF-1 remains stable. No desensitization evidence to date |
Protocol
New users, first course
On Period
Off Period
Community Rationale
Protocol
Confirmed responders
On Period
Off Period
Community Rationale
Protocol
Longevity-focused
On Period
Off Period
Community Rationale
Protocol
With regular IGF-1 monitoring
On Period
Off Period
Community Rationale
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Injection Site Guidance
Inject subcutaneously into abdominal fat. Rotate sites within the abdomen to prevent scar tissue accumulation. Maintain at least 2 cm between injection sites and avoid the 2-inch zone surrounding the navel. Standard insulin syringes (28 to 31 gauge, 6 to 8 mm needle length) are appropriate. Allow the vial to reach room temperature before injecting to reduce discomfort.
Storage
Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Never freeze a reconstituted vial. Use within the Beyond Use Date printed on the label, per USP <797> sterile compounding standards.
Section 08
Lab Monitoring (IGF-1 Is the Biomarker)
Lab monitoring is not optional with sermorelin. It is the mechanism by which you know whether the compound is working, whether your dose is appropriate, and whether you are a non-responder. Clinics that prescribe without IGF-1 monitoring at intake and at 6 to 8 weeks are not practicing responsible medicine.
The primary biomarker is IGF-1. Because GH has a short, pulsatile half-life that makes direct measurement unreliable, IGF-1 serves as the stable downstream marker of GH secretory activity. A rising IGF-1 confirms meaningful pituitary stimulation. A flat or declining IGF-1 despite consistent dosing is the most important diagnostic signal in your protocol.
IGF-1 (Insulin-Like Growth Factor 1)
Target: age-adjusted upper-normal quartile
The gold standard for sermorelin efficacy. Drawn at baseline, then at 6 to 8 weeks. Ongoing every 90 days. If IGF-1 does not rise by week 8, investigate non-response.
TSH + Free T3 + Free T4
TSH: 1.0 to 2.5 mIU/L (functional range)
Subclinical hypothyroidism is one of the most common causes of blunted sermorelin response. Test at baseline.
Fasting Glucose, Fasting Insulin, HbA1c
Fasting glucose under 100 mg/dL
Sermorelin's GH-stimulating mechanism has downstream effects on glucose metabolism. Important in patients over 55 or with metabolic syndrome.
Comprehensive Metabolic Panel + Lipids
Provider-interpreted per clinical context
CMP establishes liver and kidney function baseline. Lipid panel provides cardiovascular context. Appropriate at initiation and annually.
Section 09
Stacking
Sermorelin stacks well with peptides that operate on different pathways. Avoid stacking with other GH-axis compounds without physician oversight.
Pairs Well With
Ipamorelin
Selective GH secretagogue. Different receptor (ghrelin) means complementary, not redundant, GH stimulation. Available as combo (Sermorelin/Ipamorelin).
BPC-157
Tissue repair and gut healing. Complementary mechanism, no known interaction.
GHK-Cu
Skin and connective tissue support. Different pathway entirely.
Optimized TRT
Sermorelin layered onto established testosterone therapy is one of the highest-fit clinical applications for men 45 plus.
Approach With Caution
Exogenous HGH
Combining GH secretagogue with exogenous GH causes supraphysiologic GH levels. Physician assessment required.
MK-677 (Ibutamoren)
Oral GH secretagogue. Can cause sustained GH elevation and insulin resistance when stacked.
Glucocorticoids
Suppress GH response. Patients on chronic steroids may show blunted IGF-1 movement on sermorelin.
Multiple GH-axis compounds
Stacking three or more GH-targeting compounds increases unpredictability without proportional benefit.
Section 10
Pricing
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Other Online Clinics | $200 to $400 per month | Visit and lab fees often bundled and not disclosed publicly | Per-cycle pricing varies. Verify all-in cost and lab inclusion before committing. |
| Optimal Balance Pharmacy + RxPepsDirect | $80 per 15 mg vial, paid to pharmacy | $39 visit fee, paid to RxPepsDirect | Pre-reconstituted, FedEx overnight. Labs billed separately by your chosen lab vendor. |
| Gray Market (Research Vendor) | $30 to $70 per vial | None (no prescription) | Research-grade lyophilized powder. No physician, no IGF-1 monitoring, no labeled prescription. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Who You Pay, and What For
Pharmacy: Medication
$80 per 15 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted, FedEx overnight in a reusable cooled travel case.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation, protocol design, prescription writing, and follow-up check-ins including IGF-1 review. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 33 States
Category 1 Compoundable
Retained status in 2024 FDA PCAC review
Physician Prescription Required
Compounded medication, Rx only
Off-Label, Legal Practice
Standard and legal in U.S. medicine
The Only GHRH Analog Still Legal
CJC-1295 removed from compoundable list 12/2024
Sermorelin retained Category 1 status on the FDA bulk drug list following the December 2024 PCAC review. CJC-1295, Tesamorelin high-dose, and several other GH-axis peptides were removed from the compoundable substances list during that review. Sermorelin remains the only GHRH analog legally available through physician-supervised 503A compounding.
Off-label prescribing is a standard, legal practice in U.S. medicine. Your prescribing physician will explain the regulatory status and evidence base for your specific protocol during your consultation.
Section 12
Community Q&A
Is sermorelin the same as CJC-1295?
No. Both are GHRH analogs but the pharmacology is different. Sermorelin has a 10 to 20 minute half-life and requires daily injection. CJC-1295 with DAC had a 6 to 8 day half-life and allowed once-weekly dosing. CJC-1295 was removed from the FDA compoundable list in December 2024. Sermorelin is the only GHRH analog legally available through 503A compounding today.
Why do I have to inject every day?
Sermorelin half-life is 10 to 20 minutes. The compound is cleared from circulation quickly, which means the pituitary stimulus is brief unless you re-administer regularly. Daily dosing at bedtime, fasted, is the mechanistic requirement for meaningful IGF-1 elevation.
When will I know it is working?
Sleep changes appear earliest, often within 2 to 3 weeks. IGF-1 elevation should be measurable at 6 to 8 weeks. Body composition changes require 4 to 6 months of consistent use. Full evaluation requires 6 to 12 months. Patients who quit at 2 to 3 months are the most common preventable failure pattern.
My IGF-1 did not move at week 8. What now?
A flat IGF-1 at week 8 is the most important diagnostic signal in your protocol. Your RxPepsDirect physician will investigate dosing, adherence, sleep, thyroid function, and other variables before increasing dose or discontinuing. Roughly 30 to 40 percent of users are non-responders for reasons that range from pituitary insensitivity to subclinical hypothyroidism. Investigation is the right next step, not a higher dose.
Can I skip the labs to save money?
You can, but you should not. Without IGF-1 monitoring you have no way to know whether the compound is working. You will spend 6 months and several hundred dollars on medication without a feedback signal. Labs through Quest or LabCorp run $30 to $80 for an IGF-1 panel. That is the cheapest part of the protocol.
Will sermorelin help me lose fat?
Sermorelin can support fat loss as part of a comprehensive approach, but it is not a fat-loss agent. The IGF-1 elevation it produces enhances tissue repair, sleep architecture, and modest body composition shifts over 4 to 6 months. Sermorelin layered onto poor diet and poor sleep produces poor results.
What happens if Optimal Balance Pharmacy is out of stock?
Pharmacy supply chains can fluctuate. If Optimal Balance is temporarily unable to fill your prescription, your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 13
The RxPepsDirect Model
This guide has been direct about what sermorelin cannot deliver. It is slow. It is daily. It demands lab monitoring. Roughly 30 to 40 percent of users do not see meaningful IGF-1 movement. Within those limits, sermorelin is the only GHRH analog still legally available, has the longest human safety history of any peptide in this category, and produces sustainable benefits for patients who commit to 6 to 12 months. That is the case for the bridge model RxPepsDirect provides.
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your sermorelin under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight. The pharmacy ships the medication directly to you and bills you for the medication.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, designs your protocol, writes your prescription, and reviews your IGF-1 response data at week 6 to 8. RxPepsDirect bills the $39 medical visit fee for this service. That fee does not include medication or labs.
Transparent Safety Communication
The guide above flags the 30 to 40 percent non-responder rate, the dosing-chaos problem, the sublingual bioavailability trap, and the timeline expectations mismatch. We do not hide limitations to make a sale, because we do not profit from medication sales.
Legal Access in 33 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription. Sermorelin remains the only GHRH analog Category 1 compoundable on the FDA bulk drug list as of 2026.
References
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PMID: 9141536
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging. 2006. PMID: 18046908
- Jessup SK, Malow BA, Symons KV, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004. PMID: 15538933
- Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017. PMID: 28830317
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GHRH analog (FDA-approved as Egrifta)
Tesamorelin protocol guide: visceral fat reduction, dosing, and Phase III evidence
The only GHRH analog with Phase III trials and an FDA approval. Visceral fat reduction, the 31 percent non-responder rate, and what reaccumulates when you stop.
Growth hormone stack
CJC-1295 / Ipamorelin protocol guide: dosing, units-to-mcg, timelines, and the legal pathway
Pulsatility, DAC vs no-DAC, syringe math, the 90-day rule, gray-market purity data, and the 503A pathway. Written for the patient who wants the full picture.
Oral GH secretagogue (MK-677)
Ibutamoren (MK-677) guide: oral ghrelin receptor agonist, water retention, glucose elevation, WADA prohibition
The only oral GH secretagogue. Real GH and IGF-1 elevation. Real water retention. Real fasting-glucose drift. WADA prohibited. Monitoring is mandatory.
Continue reading